19:24:07 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-20 Bokslutskommuniké 2024
2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning DIGN 0.00 SEK
2024-05-23 Årsstämma 2024
2024-05-23 Kvartalsrapport 2024-Q1
2024-03-12 Extra Bolagsstämma 2024
2024-02-15 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 Ordinarie utdelning DIGN 0.00 SEK
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-25 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning DIGN 0.00 SEK
2022-05-19 Årsstämma 2022
2022-05-19 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning DIGN 0.00 SEK
2021-05-20 Årsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2021-01-11 Extra Bolagsstämma 2021
2020-11-19 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-26 Ordinarie utdelning DIGN 0.00 SEK
2020-06-25 Årsstämma 2020
2020-05-28 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019
2020-02-10 Extra Bolagsstämma 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-16 Ordinarie utdelning DIGN 0.00 SEK
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-15 Årsstämma 2019
2019-02-26 Bokslutskommuniké 2018
2018-11-27 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-05-22 Kvartalsrapport 2018-Q1
2018-04-27 Ordinarie utdelning DIGN 0.00 SEK
2018-04-26 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-12-04 Extra Bolagsstämma 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-06-02 Årsstämma 2017
2017-05-24 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-11-24 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-25 Kvartalsrapport 2016-Q1
2016-03-23 Ordinarie utdelning DIGN 0.00 SEK
2016-03-22 Årsstämma 2016
2016-02-24 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-05-19 Ordinarie utdelning DIGN 0.00 SEK
2015-02-24 Bokslutskommuniké 2014
2014-11-25 Kvartalsrapport 2014-Q3
2014-08-26 Kvartalsrapport 2014-Q2
2014-05-20 Kvartalsrapport 2014-Q1
2014-05-19 Ordinarie utdelning DIGN 0.00 SEK
2014-05-16 Årsstämma 2014
2014-03-04 Extra Bolagsstämma 2014
2014-02-27 Bokslutskommuniké 2013
2013-11-28 Kvartalsrapport 2013-Q3
2013-08-28 Kvartalsrapport 2013-Q2
2013-08-28 Extra Bolagsstämma 2013
2013-05-22 Kvartalsrapport 2013-Q1
2013-05-22 Ordinarie utdelning DIGN 0.00 SEK
2013-05-21 Årsstämma 2013
2013-02-27 Bokslutskommuniké 2012
2012-11-28 Kvartalsrapport 2012-Q3
2012-10-30 Extra Bolagsstämma 2012
2012-09-28 Kapitalmarknadsdag 2012
2012-08-28 Kvartalsrapport 2012-Q2
2012-06-29 Årsstämma 2012
2012-05-28 Kvartalsrapport 2012-Q1
2012-02-27 Bokslutskommuniké 2011
2011-11-17 Kvartalsrapport 2011-Q3
2011-08-22 Kvartalsrapport 2011-Q2
2011-06-13 Ordinarie utdelning DIGN 0.00 SEK
2011-06-10 Årsstämma 2011
2011-05-30 Kvartalsrapport 2011-Q1
2011-02-25 Bokslutskommuniké 2010
2010-11-18 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-06-21 Ordinarie utdelning DIGN 0.00 SEK
2010-05-18 Kvartalsrapport 2010-Q1
2010-02-18 Bokslutskommuniké 2009
2009-12-21 Split DIGN 100:1
2009-11-18 Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Dignitana är verksamt inom medicinteknik. Bolaget utvecklar, tillverkar och marknadsför medicinska hjälpmedel som primärt används som skalpkylningssystem vid cytostatikabehandling, vars syfte är att eliminera eller kraftigt reducera håravfall. Bolaget har global verksamhet främst inom Norden, Europa, Nordamerika och Asien. Dignitana grundades år 2007 och har sitt huvudkontor i Lund.
2021-12-21 08:00:00

Dignitana CEO William Cronin has notified the Board of Directors of his intention to resign as CEO. He will remain as CEO until the Dignitana AGM in May, after which time he will transition to serve as Deputy Chairman of the Board of Directors and will be a Senior Advisor to the company regarding US market and reimbursement strategies.

The process of recruiting a successor will begin immediately for a new CEO who will be based at the Company headquarters in Lund along with other key positions for the Company.

Klas Arildsson, Chairman of the Board, Dignitana AB:

"Dignitana's clear strategy is to expand and further strengthen both the primary US market and our presence around the globe.  I want to thank William for his hard work, passion, and perseverance. We are now at an exciting stage with a solid foundation and great opportunities before us.  Under his leadership we have accessed significant US opportunities and regained the company's position as a leader in innovation. William's ongoing involvement with Dignitana will ensure not only a smooth transition to the new CEO, but also continued strategic expansion in the critical US market."

William Cronin, CEO, Dignitana AB:

"I am pleased with what we have accomplished over the past six years, especially the establishment of DigniCap in the US market, bringing this life changing therapy to thousands of people. One of our greatest assets is the passion and commitment of our team members, and I have been fortunate to see that impact every day. Dignitana has strong potential for growth in the near-term and I will remain actively involved in the company as a Senior Advisor focusing on the expansion of the US market access, as well as a member of the Board and as a significant shareholder."

William Cronin has been CEO of Dignitana AB since November 2017. He previously served as CEO of Dignitana, Inc. beginning in December 2015 when the company's U.S. subsidiary was established. Under his leadership DigniCap became the first scalp cooling device to receive FDA clearance, with clinical indications then expanded in 2017. Cronin then led the development of the next generation DigniCap Delta device which received FDA clearance in 2019.